Mutagenic potential of DNA glycation: miscoding by (R)- and (S)-N2-(1-carboxyethyl)-2'-deoxyguanosine.
Elevated circulating glucose resulting from complications of obesity and metabolic disease can result in the accumulation of advanced glycation end products (AGEs) of proteins, lipids, and DNA. The formation of DNA-AGEs assumes particular importance as these adducts may contribute to genetic instability and elevated cancer risk associated with metabolic disease. The principal DNA-AGE, N(2)-(1-carboxyethyl)-2'-deoxyguanosine (CEdG), is formed as a mixture of R and S isomers at both the polymer and monomer levels. In order to examine the miscoding potential of this adduct, oligonucleotides substituted with (R)- and (S)-CEdG and the corresponding triphosphates (R)- and (S)-CEdGTP were synthesized, and base-pairing preferences for each stereoisomer were examined using steady-state kinetic approaches. Purine dNTPs were preferentially incorporated opposite template CEdG when either the Klenow (Kf(-)) or Thermus aquaticus (Taq) polymerases were used. The Kf(-) polymerase preferentially incorporated dGTP, whereas Taq demonstrated a bias for dATP. Kf(-) incorporated purines opposite the R isomer with greater efficiency, but Taq favored the S isomer. Incorporation of (R)- and (S)-CEdGTP only occurred opposite dC and was catalyzed by Kf(-) with equal efficiencies. Primer extension from a 3'-terminal CEdG was observed only for the R isomer. These data suggest CEdG is the likely adduct responsible for the observed pattern of G transversions induced by exposure to elevated glucose or its alpha-oxoaldehyde decomposition product methylglyoxal. The results imply that CEdG within template DNA and the corresponding triphosphate possess different syn/anti conformations during replication which influence base-pairing preferences. The implications for CEdG-induced mutagenesis in vivo are discussed.
Department of Molecular Medicine, Beckman Research Institute of theCity of Hope, 1500 Duarte Road, Duarte, California 91010, USA.
Gerald E
GE
Wuenschell
Daniel
D
Tamae
Angelique
A
Cercillieux
Rio
R
Yamanaka
Calvin
C
Yu
John
J
Termini
D020137:Base Pair Mismatch / Q000235:genetics*; D002384:Catalysis; D018736:DNA Adducts / Q000138:chemical synthesis / Q000235:genetics / Q000378:metabolism; D003845:Deoxycytosine Nucleotides / Q000737:chemistry / Q000235:genetics; D003854:Deoxyribonucleotides / Q000138:chemical synthesis / Q000235:genetics / Q000378:metabolism; D017127:Glycation End Products, Advanced / Q000737:chemistry* / Q000235:genetics*; D006031:Glycosylation; D006151:Guanosine / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000235:genetics / Q000378:metabolism; D006801:Humans; D009152:Mutagenicity Tests; D009153:Mutagens / Q000138:chemical synthesis* / Q000378:metabolism; D013237:Stereoisomerism; D013698:Templates, Genetic
D018736:DNA Adducts; D003845:Deoxycytosine Nucleotides; D003854:Deoxyribonucleotides; D017127:Glycation End Products, Advanced; D009153:Mutagens; C116679:N(2)-(1-(1-carboxy)ethyl)guanosine; D006151:Guanosine; C024107:2'-deoxycytidine 5'-triphosphate